Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.48 |
| ▸ | NCF1 | P14598 | 4/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808587 | 0.89 | P2RY12 (0.53) | ALOX15P2RY12NCF1ALDH1A1 | |
| SCHEMBL9379922 | 0.86 | ALOX15 (0.52) | ALOX15P2RY12NCF1PLA2G2AKDM4E | |
| SCHEMBL31389258 | 0.86 | ALOX15 (0.52) | ALOX15P2RY12NCF1PLA2G2AKDM4E | |
| SCHEMBL31389238 | 0.85 | ALOX15 (0.57) | ALOX15P2RY12PLA2G2AKDM4ETP53 | |
| SCHEMBL31389291 | 0.85 | ALOX15 (0.51) | ALOX15P2RY12NCF1KDM4EALDH1A1 | |
| SCHEMBL31389266 | 0.83 | ALOX15 (0.55) | ALOX15ALDH1A1HPGDTP53 | |
| SCHEMBL9381350 | 0.83 | ALOX15 (0.55) | ALOX15P2RY12KDM4EALDH1A1 | |
| SCHEMBL20515870 | 0.83 | ALOX15 (0.69) | ALOX15P2RY12NCF1KDM4EALDH1A1 | |
| SCHEMBL30438659 | 0.83 | ALOX15 (0.69) | ALOX15P2RY12NCF1KDM4EALDH1A1 | |
| SCHEMBL2072605 | 0.82 | ALOX15 (0.77) | ALOX15P2RY12KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | ALOX15 973/4885P2RY12 1957/4885NCF1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.